3/18/2010 3:41:59 PM
Oxford, UK – 18 March 2010. Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has today announced that it has signed an exclusive distribution agreement with Kreatech Diagnostics (Amsterdam, The Netherlands). The deal will enable Kreatech Diagnostics to sell OGT’s CytoSure™ products throughout France, providing customers with a comprehensive aCGH solution. Speaking ahead of the announcement, Mike Evans, CEO of OGT said: “We are delighted to sign this distribution deal. Kreatech has vast experience and a broad customer base in the genomic arena, and is therefore perfectly positioned to market our CytoSure range in France."
Commenting on the agreement, Harald Berninger, VP Sales and Marketing at Kreatech said: “OGT’s CytoSure products are the only arrays with content specifically optimised for the cytogenetic community. This advanced aCGH range represents the next step in cytogenetics from our FISH probes. Through the distribution of OGT’s CytoSure we are now able to package the arrays with our unique ULSTM labelling technology, offering our customers a complete consumable solution."
OGT’s CytoSure aCGH product line comprises a range of high quality arrays covering single disorders through to syndrome focussed, genome wide coverage. The CytoSure arrays, including the International Standard Cytogenomic Array (ISCA) Consortium-approved series, meet the resolution, multiplexing and budget requirements of both cytogeneticists and molecular biologists. Furthermore, each CytoSure array comes with CytoSure Interpret Software for effortless translation of data into meaningful results. The software allows fast and standardised data analysis through customisable workflows, automatic aberration identification, and comprehensive contextual input via integration with public aberration databases (e.g. Decipher and the Database of Genomic Variants) and the facility to build and share institutional databases.
About Oxford Gene Technology
Founded in 1995 by Professor Ed Southern, OGT has a proven pedigree in microarray technology and services. Our mission is to advance molecular medicine through pioneering discovery and application of molecular technologies. OGT’s key focus areas are: high throughput genomic services and biomarker discovery, cytogenetics, single cell analysis, and licensing.
OGT’s genomic services (Genefficiency™) offer a unique combination of industry leading platforms, expert people, unparalleled sample processing power and performance, to rapidly deliver high quality genomic data to customers worldwide.
OGT’s products and services for cytogenetics (CytoSure™) include a range of high resolution oligonucleotide arrays, labelling kits and interpretation software that together provide a complete solution for the detection of chromosomal abnormalities
Together, Genefficiency™ and CytoSure™ offer a unique, standardised and integrated solution for disease and cytogenetics research.
About Kreatech Diagnostics
Based in Amsterdam, The Netherlands, Kreatech Diagnostics is a molecular diagnostics company focused on the development and commercialization of DNA probes and nucleic acid labeling technologies that are utilized for diagnostics and research applications in the life sciences and healthcare industry, specifically cytogenetics, molecular pathology, and microarrays. Kreatech is positioned as the partner of choice for the world’s leading drug discovery, pharmaceutical, diagnostics and life sciences companies.
Visit www.kreatech.com for more information.
comments powered by